Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy.
OBJECTIVE
Donor T cells directed to hematopoietic minor histocompatibility antigens (mHag) are appealing tools for adoptive immunotherapy of hematological malignancies after allogeneic stem cell transplantation (allo-SCT). Toward the development of a convenient strategy for ex vivo generation of human leukocyte antigen (HLA) class II--restricted mHag-specific T cells, we evaluated the feasibility of rebuilding mHag-specific T cell functions in donor-derived recall antigen-specific T cells via T cell receptor (TCR) transfer.


METHODS
TCR alpha- and beta-chains of an HLA-DPB1*0401--restricted T-cell clone recognizing a multiple myeloma-associated mHag were retrovirally transferred into a tetanus toxoid (TT)--specific clone derived from the original stem cell donor. TCR double-transduced cells were compared with the parent mHag- and TT-specific clones for antigen specificity, cytokine secretion, and cytotoxic activity and were analyzed for their in vitro expansion capacity in a TT- or mHag-specific fashion.


RESULTS
mHag-TCR--transduced TT-specific cells displayed both TT and mHag specificity. Similar to the parent cells, they secreted Th-1 cytokines and exerted significant cytotoxic activity against TT-pulsed or mHag(+) target cells, including multiple myeloma cells. A 4-week expansion of TCR-transduced cells via the TT-specific TCR had no negative influence on the mHag-specific cytotoxic activity and resulted in 10- to 100-fold better cell yields as compared with mHag-specific expansion.


CONCLUSIONS
HLA class II--restricted, mHag-specific effector functions can be successfully reconstructed in donor-derived TT-specific T cells via TCR transfer. Effective expansion of these T cells via TT-specific TCRs illustrate the suitability of this strategy for ex vivo expansion and possibly for in vivo TT-specific reboosting of HLA class II--restricted immunotherapeutic T cells.
Spaapen
Robbert
R
Authors' Affiliations: Departments of Clinical Chemistry and Haematology, Immunology, and Haematology, University Medical Center Utrecht, the Netherlands.
van den Oudenalder
Kelly
K
Ivanov
Roman
R
Bloem
Andries
A
Lokhorst
Henk
H
Mutis
Tuna
T
D019264:Adoptive Transfer; D045744:Cell Line, Tumor; D002469:Cell Separation; D017690:Cell Transplantation; D003001:Cloning, Molecular; D005434:Flow Cytometry; D000949:Histocompatibility Antigens Class II / Q000235:genetics*; D006801:Humans; D016130:Immunophenotyping; D016219:Immunotherapy, Adoptive / Q000379:methods*; D015778:Minor Histocompatibility Antigens / Q000737:chemistry*; D009101:Multiple Myeloma / Q000378:metabolism; D012190:Retroviridae / Q000235:genetics; D013601:T-Lymphocytes / Q000737:chemistry / Q000276:immunology*; D013997:Time Factors
D000949:Histocompatibility Antigens Class II; D015778:Minor Histocompatibility Antigens